OnKure Therapeutics, Inc.
For the period ended Mar 31, 2026. Filed May 5, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 5, 2026
OKUR$3.39+6.1%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Changes in Stockholders’ Equity
(in thousands, except share information)
| Additional · Total | |||||||
|---|---|---|---|---|---|---|---|
| Class A Common Stock · Class B Common Stock · Paid-In · Accumulated · Stockholders' | |||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Equity | |
| Balance, December 31, 2024 | 12,660,590 | $1 | 686,527 | $— | $258,551 | $(154,724) | $103,828 |
| Vesting of restricted stock units, net | 94,758 | — | — | — | — | — | — |
| Share-based compensation | — | — | — | — | 2,745 | — | 2,745 |
| Net loss | — | — | — | — | — | (15,925) | (15,925) |
| Balance, March 31, 2025 | 12,755,348 | 1 | 686,527 | — | 261,296 | (170,649) | 90,648 |
| Vesting of restricted stock units | 88,086 | — | — | — | — | — | — |
| Share-based compensation | — | — | — | — | 2,908 | — | 2,908 |
| Net loss | — | — | — | — | — | (15,390) | (15,390) |
| Balance, June 30, 2025 | 12,843,434 | 1 | 686,527 | — | 264,204 | (186,039) | 78,166 |
| Vesting of restricted stock units | 18,238 | — | — | — | — | — | — |
| Share-based compensation | — | — | — | — | 2,961 | — | 2,961 |
| Net loss | — | — | — | — | — | (14,699) | (14,699) |
| Balance, September 30, 2025 | 12,861,672 | 1 | 686,527 | — | 267,165 | (200,738) | 66,428 |
| Conversion of Class B Common Stock to Class A Common Stock | 686,527 | — | (686,527) | — | — | — | — |
| Issuance of Class A Common Stock under the Employee Stock Purchase Plan | 107,930 | — | — | — | 240 | — | 240 |
| Vesting of restricted stock units | 17,436 | — | — | — | — | — | — |
| Share-based compensation | — | — | — | — | 3,019 | — | 3,019 |
| Net loss | — | — | — | — | — | (13,503) | (13,503) |
| Balance, December 31, 2025 | 13,673,565 | 1 | — | — | 270,424 | (214,241) | 56,184 |
| Issuance of Class A Common Stock and pre-funded warrants in connection with 2026 Private Placement, less issuance costs | 26,713,638 | 3 | — | — | 140,543 | — | 140,546 |
| Vesting of restricted stock units | 8,277 | — | — | — | — | — | — |
| Share-based compensation | — | — | — | — | 2,780 | — | 2,780 |
| Net loss | — | — | — | — | — | (15,157) | (15,157) |
| Balance, March 31, 2026 | 40,395,480 | $4 | — | $— | $413,747 | $(229,398) | $184,353 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.